New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 24, 2014
07:32 EDTCELG, XLRNCelgene, Acceleron announce two publications on ACE-536
Celgene Corporation (CELG) and Acceleron Pharma (XLRN), announced the publication of two papers available online today and in the April issue of the journal Nature Medicine that describe how sotatercept and ACE-536 promote red blood cell formation through an erythropoietin independent mechanism in mice. EPO stimulates the proliferation of early-stage red blood cell precursors to form new red blood cells. However, anemias associated with defects in the late-stages of red blood cell formation, known as ineffective erythropoiesis, are resistant to EPO treatment. These studies suggest that sotatercept and ACE-536 may promote and regulate the maturation of late-stage red blood cell precursors and this distinct activity supports the rationale for sotatercept and ACE-536 as potential novel therapies to correct anemia, including the EPO-resistant anemia, in diseases such as beta-thalassemia and myelodysplastic syndromes. The two papers provide evidence that at least one TGF-beta superfamily member, GDF-11, reduces the maturation of late-stage red blood cell precursors that can cause anemia. In these models, the mouse versions of sotatercept and ACE-536 block GDF-11, among other ligands, stimulating the maturation of red blood cell precursors and restoring the production of functional red blood cells in mouse models of myelodysplastic syndromes and beta-thalassemia.
News For XLRN;CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 6, 2015
08:01 EDTXLRNAcceleron names Steven Ertel as EVP, COO and Matthew Sherman as EVP, CMO
Acceleron Pharma announced two executive promotions and appointments from within the organization. Steven Ertel has been named Executive VP and COO; he previously held the title of Senior VP and Chief Business Officer. In addition, Matthew L. Sherman, M.D., has been promoted to Executive VP and Chief Medical Officer.
March 4, 2015
12:11 EDTCELGCelgene reaffirms long-term financial targets
Celgene in conference presentation slides reaffirmed its 2017 product sales target of $13B-$14B and 2020 target of over $20B. The company also reaffirmed its 2017 earnings per share target of $7.50 and 2020 target of greater than $12.50. Celgene said it is on track to meet or exceed its 2017 targets. It expects "strong growth" to 2020 by on label expansions and new products.
09:36 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AA AMZN CELG MCD SINA TSLA V TWTR PBR
March 3, 2015
11:46 EDTCELGLeerink biotech analyst holds an analyst/industry conference call
Subscribe for More Information
March 2, 2015
09:46 EDTCELGCelgene announces EC approved Abraxane
Subscribe for More Information
09:34 EDTCELGActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL MNTA CELG TSLA MCD ARUN GILD KO TWTR NFLX
07:40 EDTXLRNAcceleron reports Q4 EPS (55c), consensus (23c)
Reports Q4 revenue $3.74M, consensus $9.58M.
March 1, 2015
12:24 EDTXLRNAcceleron reports new data from Dart study on dalantercept in patients with RCC
Acceleron Pharma reported new preliminary data from the DART study, an ongoing phase 2 clinical trial of dalantercept in patients with advanced renal cell carcinoma, RCC. The preliminary data from part 1 of the DART study were presented in an oral session at the American Society of Clinical Oncology, ASCO, 2015 Genitourinary Cancers Symposium held in Orlando, Florida on February 28. “These promising response rates and progression-free survival data suggest that the dual angiogenesis blockade of ALK1 and VEGFR signaling with dalantercept and axitinib may provide additive efficacy compared to VEGFR inhibitor therapy alone,” said Matthew Sherman, M.D., Chief Medical Officer of Acceleron. “The results from part 1 of this study provide encouraging evidence of the safety and activity of this combination of two distinct anti-angiogenic agents in previously treated patients with advanced RCC,” said Martin H. Voss, M.D., medical oncologist at Memorial Sloan Kettering Cancer Center and lead investigator for the trial. “We look forward to building on these results in the randomized part 2 of the ongoing DART trial.”
February 27, 2015
07:37 EDTCELGCelgene removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
February 25, 2015
13:44 EDTCELGCelgene price target raised to $155 from $130 at Argus
Argus increased its price target on Celgene as the firm thinks the company is "well on its way" to meeting its growth targets. The firm thinks the company reported strong Q4 results and keeps a Buy rating on the shares.
February 24, 2015
08:04 EDTCELGCelgene reports Abraxane now reimbursed in Italy as first-line treatment
Celgene International Sŕrl, a wholly owned subsidiary of Celgene Corporation, announced that Italian authorities have issued a positive decision for NHS reimbursement of ABRAXANE -- paclitaxel formulated as albumin-bound nanoparticles, or nab-paclitaxel -- in combination with gemcitabine, for the first-line treatment of patients with metastatic adenocarcinoma of the pancreas, or pancreatic cancer. The reimbursement decision has been published in the Italian Official Gazette no. 30, dated February 6, 2015.
07:31 EDTCELGRBC Capital to hold a conference
Subscribe for More Information
February 23, 2015
07:22 EDTXLRNSunTrust to hold a conference
2015 Biotechnology and Pharmaceutical 1:1 Orphan Drug Day is being held in New York on February 23.
February 20, 2015
16:03 EDTCELGOptions Update; February 20, 2015
Subscribe for More Information
09:38 EDTCELGActive equity options trading on open
Subscribe for More Information
05:27 EDTCELGCelgene Revlimid approved by EC
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use